• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑脊液蛋白质组学定义常染色体显性阿尔茨海默病的自然史。

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.

机构信息

Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Nat Med. 2023 Aug;29(8):1979-1988. doi: 10.1038/s41591-023-02476-4. Epub 2023 Aug 7.

DOI:10.1038/s41591-023-02476-4
PMID:37550416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10427428/
Abstract

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes-aggregation of the amyloid-β (Aβ) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)-are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aβ plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aβ plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aβ and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aβ and tau.

摘要

阿尔茨海默病(AD)的病理变化在认知症状出现前多年就已开始。两种病理过程——β淀粉样蛋白(Aβ)肽聚集成斑块和微管蛋白 tau 聚集成神经原纤维缠结(NFTs)——是该疾病的标志。然而,人们认为其他病理脑过程是 Aβ斑块和 NFT 病理的关键疾病介质。目前尚不清楚这些额外的病理过程在疾病过程中是如何演变的。在这里,我们展示了与脑蛋白共表达相关的常染色体显性 AD 脑脊液(CSF)中的蛋白质组学测量可以用于描述 AD 病理学在跨越六十年的时间尺度上的演变。与 Aβ斑块相关的 SMOC1 和 SPON1 蛋白在症状出现前近 30 年就出现在 AD CSF 中,随后是突触蛋白、代谢蛋白、轴突蛋白、炎症蛋白和最后是神经分泌蛋白的变化。该蛋白质组在症状出现前就能够区分突变携带者和非携带者,其效果与 Aβ和 tau 测量一样好,甚至更好。我们的结果突出了 AD 病理生理学及其时间演变的多方面性。这种知识对于开发超越 Aβ和 tau 的 AD 精准治疗干预措施和生物标志物至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/2630b54fafce/41591_2023_2476_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/f59c8d45901d/41591_2023_2476_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/279f9e5997a2/41591_2023_2476_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/1851410afaa7/41591_2023_2476_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/d808575c0324/41591_2023_2476_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/2630b54fafce/41591_2023_2476_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/f59c8d45901d/41591_2023_2476_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/279f9e5997a2/41591_2023_2476_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/1851410afaa7/41591_2023_2476_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/d808575c0324/41591_2023_2476_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/2630b54fafce/41591_2023_2476_Fig5_ESM.jpg

相似文献

1
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.脑脊液蛋白质组学定义常染色体显性阿尔茨海默病的自然史。
Nat Med. 2023 Aug;29(8):1979-1988. doi: 10.1038/s41591-023-02476-4. Epub 2023 Aug 7.
2
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
3
Ubiquitin-proteasome system in the different stages of dominantly inherited Alzheimer's disease.常染色体显性遗传阿尔茨海默病不同阶段的泛素-蛋白酶体系统
Alzheimers Dement. 2025 May;21(5):e70243. doi: 10.1002/alz.70243.
4
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease.与晚发性和常染色体显性阿尔茨海默病相比,唐氏综合征脑脊液的蛋白质组学分析
Nat Commun. 2025 Jul 1;16(1):6003. doi: 10.1038/s41467-025-61054-z.
5
SMOC1 colocalizes with Alzheimer's disease neuropathology and delays Aβ aggregation.SMOC1 与阿尔茨海默病神经病理学共存,并延缓 Aβ 聚集。
Acta Neuropathol. 2024 Nov 25;148(1):72. doi: 10.1007/s00401-024-02819-6.
6
Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.遗传风险作为脑脊液中β淀粉样蛋白和tau蛋白负荷的标志物
J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.
7
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.非裔美国人和白种人脑脊液的定量蛋白质组学研究揭示了阿尔茨海默病的共同和差异变化。
Mol Neurodegener. 2023 Jul 19;18(1):48. doi: 10.1186/s13024-023-00638-z.
8
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.多分析物蛋白质组学分析鉴定出临床前阿尔茨海默病患者血液中的神经炎症、脑血管和突触生物标志物。
Mol Neurodegener. 2024 Oct 10;19(1):68. doi: 10.1186/s13024-024-00753-5.
9
Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with ε4 and atomoxetine treatment.阿尔茨海默病脑脊液蛋白质组学分析显示与 ε4 和托莫西汀治疗相关的改变。
Sci Transl Med. 2024 Jun 26;16(753):eadn3504. doi: 10.1126/scitranslmed.adn3504.
10
γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).γ-分泌酶活性、临床特征和常染色体显性阿尔茨海默病的生物标志物:显性遗传性阿尔茨海默病网络观察研究(DIAN-OBS)的横断面和纵向分析。
Lancet Neurol. 2024 Sep;23(9):913-924. doi: 10.1016/S1474-4422(24)00236-9. Epub 2024 Jul 26.

引用本文的文献

1
Bridging Health Disparity Gaps in Alzheimer's Disease among Marginalized Populations: Clinical Proteomics as a Case Study.弥合边缘化人群中阿尔茨海默病的健康差距:以临床蛋白质组学为例
ACS Bio Med Chem Au. 2025 Jul 8;5(4):505-518. doi: 10.1021/acsbiomedchemau.5c00074. eCollection 2025 Aug 20.
2
Morphology of the glymphatic and meningeal lymphatic structures of the bottlenose dolphin.宽吻海豚脑周淋巴系统和脑膜淋巴结构的形态学
Sci Rep. 2025 Aug 18;15(1):30216. doi: 10.1038/s41598-025-14840-0.
3
Immunoassay for pyruvate kinase M1/2 as an Alzheimer's biomarker in CSF.

本文引用的文献

1
Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.阿尔茨海默病脑脊液蛋白质生物标志物的定量质谱分析。
Sci Data. 2023 May 9;10(1):261. doi: 10.1038/s41597-023-02158-3.
2
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae.实验证据表明,大脑 Aβ 沉积与神经退行性病变后果之间存在时间上的解偶联。
Nat Commun. 2022 Nov 28;13(1):7333. doi: 10.1038/s41467-022-34538-5.
3
Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
脑脊液中丙酮酸激酶M1/2作为阿尔茨海默病生物标志物的免疫测定法。
Open Life Sci. 2025 Jul 7;20(1):20251101. doi: 10.1515/biol-2025-1101. eCollection 2025.
4
Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Disease Pathology and Progression.路易体痴呆的多重蛋白质组学揭示了疾病病理和进展的脑脊液生物标志物。
bioRxiv. 2025 Jun 13:2025.06.10.658994. doi: 10.1101/2025.06.10.658994.
5
Proteomic landscape of Alzheimer's disease: emerging technologies, advances and insights (2021 - 2025).阿尔茨海默病的蛋白质组学全景:新兴技术、进展与见解(2021 - 2025年)
Mol Neurodegener. 2025 Jul 14;20(1):83. doi: 10.1186/s13024-025-00874-5.
6
Systematic Investigations of the Huperzine A-Producing Endophytic Fungi of in China and Fermentation Optimization Using OSMAC Strategy.中国产石杉碱甲内生真菌的系统研究及基于OSMAC策略的发酵优化
Molecules. 2025 Jun 23;30(13):2704. doi: 10.3390/molecules30132704.
7
Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.神经退行性疾病中靶向小胶质细胞的生物标志物与治疗策略:现状与未来方向
Mol Neurodegener. 2025 Jul 10;20(1):82. doi: 10.1186/s13024-025-00867-4.
8
Machine-learning based strategy identifies a robust protein biomarker panel for Alzheimer's disease in cerebrospinal fluid.基于机器学习的策略识别出用于阿尔茨海默病的脑脊液中强大的蛋白质生物标志物组。
Alzheimers Res Ther. 2025 Jul 4;17(1):147. doi: 10.1186/s13195-025-01789-5.
9
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease.与晚发性和常染色体显性阿尔茨海默病相比,唐氏综合征脑脊液的蛋白质组学分析
Nat Commun. 2025 Jul 1;16(1):6003. doi: 10.1038/s41467-025-61054-z.
10
Epigenome-wide association study of cerebrospinal fluid-based biomarkers of Alzheimer's disease in cognitively normal individuals.认知正常个体中基于脑脊液的阿尔茨海默病生物标志物的全表观基因组关联研究。
Alzheimers Dement. 2025 Jun;21(6):e70318. doi: 10.1002/alz.70318.
阿尔茨海默病脑脊液和血浆的多平台蛋白质组学分析揭示了与蛋白质平衡和基质体相关的网络生物标志物。
Alzheimers Res Ther. 2022 Nov 17;14(1):174. doi: 10.1186/s13195-022-01113-5.
4
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.载脂蛋白 E 在阿尔茨海默病中的作用:发病机制与治疗策略。
Mol Neurodegener. 2022 Nov 8;17(1):72. doi: 10.1186/s13024-022-00574-4.
5
Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum.反应性星形胶质细胞增生与阿尔茨海默病连续体早期的大脑葡萄糖消耗增加有关。
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4567-4579. doi: 10.1007/s00259-022-05897-4. Epub 2022 Jul 18.
6
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.阿尔茨海默病中的 Tau 生物标志物:迈向临床实践和试验的应用。
Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25.
7
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.常染色体显性遗传和散发性晚发性阿尔茨海默病具有共同的体内病理生理学。
Brain. 2022 Oct 21;145(10):3594-3607. doi: 10.1093/brain/awac181.
8
The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives.骨桥蛋白在小胶质细胞生物学中的作用:当前概念与未来展望
Biomedicines. 2022 Apr 3;10(4):840. doi: 10.3390/biomedicines10040840.
9
CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease.CSF Tau 磷酸化在 Thr205 处与常染色体显性阿尔茨海默病的白质完整性丧失有关。
Neurobiol Dis. 2022 Jun 15;168:105714. doi: 10.1016/j.nbd.2022.105714. Epub 2022 Mar 28.
10
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.脑脊液可溶性 TREM2 及其与其他生物标志物和常染色体显性阿尔茨海默病认知的关系:一项纵向观察研究。
Lancet Neurol. 2022 Apr;21(4):329-341. doi: 10.1016/S1474-4422(22)00027-8.